Double hit lymphoma: from biology to therapeutic implications.

about

The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.Cytologic perspectives on neoteric B-cell lymphoproliferative disorders.Genetics of diffuse large B cell lymphoma.Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective

P2860

Q39018438-D65E353B-9F3D-4839-AB33-66EC3621390B Q39359287-18611520-B579-4228-877C-7D43920E1605 Q52582248-79899661-2DC6-4AF6-B70F-92945C353F00 Q57174502-F694A8D0-84E8-4FB5-ADF8-03EFCA8CB100

P2860

Double hit lymphoma: from biology to therapeutic implications.

Item

http://www.wikidata.org/entity/Q38831667

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Double hit lymphoma: from biology to therapeutic implications.

@en

type

Item

label

Double hit lymphoma: from biology to therapeutic implications.

@en

prefLabel

Double hit lymphoma: from biology to therapeutic implications.

@en

P1476

Double hit lymphoma: from biology to therapeutic implications.

@en

P2093

Alejandro Berkovits

http://www.w3.org/2001/XMLSchema#string

Kieron Dunleavy

http://www.w3.org/2001/XMLSchema#string

Mauricio Burotto

http://www.w3.org/2001/XMLSchema#string

P2860

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Aggressive lymphomas

P304

669-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/17474086.2016.1182858

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27166590

http://www.w3.org/2001/XMLSchema#string

Double hit lymphoma: from biology to therapeutic implications.

about

P2860

P2860

Double hit lymphoma: from biology to therapeutic implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698